The signal transducer and activator of transcription 6 (STAT6) transcription factor activates peroxisome proliferator-activated receptor gamma (PPAR-)-regulated gene expression in immune cells. We investigated proximal membrane signaling that was initiated in macrophages after exposure to apoptotic cells that led to enhanced PPAR-expression and activity, using 
different cell types. [17] [18] [19] However, PPAR-expression and the presence of appropriate ligands are usually insufficient to elicit optimal or maximal effects. 20 Here, we aimed to understand the impact of proximal signal transduction that leads to PPAR-activation in macrophages after exposure to apoptotic cells. Signal transducer and activator of transcription 6 (STAT6) acts as a facilitating factor for PPAR-by promoting DNA binding and consequently increasing the number of regulated genes and the magnitude of responses. 20 Although IL-4 and IL-13 are known as primary activators of STAT6, these cytokines were not shown to stimulate STAT6 phosphorylation following in vivo exposure to apoptotic cells, since apoptotic cell instillation after bleomycin treatment did not affect or even reduce BLM-induced IL-4 and IL-13 in bronchoalveolar lavage fluid. 13 On the other hand, several reports have demonstrated that ATP-binding cassette transporter A1 (ABCA1), in association with apolipoprotein A-1 (ApoA-1), can activate the JAK/STAT pathway. [21] [22] [23] Moreover, apoptotic cell clearance has been linked to ABCA1 expression in macrophages 24, 25 ; however, the precise mechanism involved remains poorly understood.
Using specific siRNAs to ABCA1, STAT6, and PPAR-, we investigated proximal membrane signaling that was initiated in macrophages after exposure to apoptotic cells, leading to enhanced PPAR-expression and activity. Our data show that apoptotic cells trigger the ABCA1/STAT6 pathway, leading to PPAR-activation as well as LXRand ABCA1 induction in mouse bone marrow-derived macrophages (BMDMs) and RAW 264.7 cells. Our results suggest that macrophage recognition of apoptotic cells could reinforce the ABCA1/STAT6 pathway via the PPAR-/LXR-/ABCA1 pathway in a feedforward manner.
MATERIALS AND METHODS

Reagents
BLM and paraformaldehyde were purchased from Sigma-Aldrich (St.
Louis, MO). The antibodies used for western blotting are as follows:
anti-phospho-STAT6 (Tyr-641), anti-STAT6, anti-PPAR-, anti-histone H1 (Santa Cruz Biotechnology, Santa Cruz, CA), anti-LXR-(Abcam, Cambridge, UK), anti-ABCA1 (Novus Biologicals, Littleton, CO), anti--actin, and anti--tubulin (Sigma-Aldrich). AS1517499 (Axon Medchem BV, Groningen, Netherlands) and GW9662 (Cayman Chemical Co., Ann Arbor, MI) were used, according to the manufacturers' instructions.
The Gene-Specific Relative RT-PCR kit was obtained from Invitrogen (Carlsbad, CA, USA). M-MLV reverse transcriptase was from Enzynomics (Hanam, Korea).
Cell culture and exposure to apoptotic cells
Primary BMDMs were prepared from BALB/C mice, as described previously. 26 Briefly, BMDMs were differentiated from murine bone marrow myeloid stem cells. Bone marrow cells were cultured for 7-10 days with DMEM supplemented with 10% L929 supernatant containing 10% heat-inactivated FBS, 1 mM sodium pyruvate, 50 U/mL penicillin, 50 g/mL streptomycin, and 50 M 2-mercaptoethanol.
BMDM differentiation was confirmed by FACS analysis using antiCD11b antibodies. BMDMs were plated at 1 × 10 6 cells/mL and then stimulated with apoptotic Jurkat T cells (3 × 10 6 cells/mL) in serum-free medium for the times indicated in the figure legends.
Murine RAW264.7 cells [American Type Culture Collection, Manassas, VA] were plated at 1 × 10 6 cells/mL and then stimulated with either apoptotic or viable Jurkat T cells (3 × 10 6 cells/mL) in serum-free medium for the times indicated in the figure legends. The RAW 264.7 cell phenotype was always assessed before each experiment, and cells were used within two passages.
Induction of apoptosis
Human T lymphocyte Jurkat cells were obtained from the American Type Culture Collection (Rockville, MD). Apoptosis was induced by UV irradiation at 254 nm for 10 min. The cells were then incubated for 2.5 h before use. Cells were approximately 70% apoptotic, according to a determination of their nuclear morphology by light microscopy. 27 
Transient cell transfection with siRNAs
Nuclear extracts
After 24 h of exposure to apoptotic or viable Jurkat cells, the cells were harvested and resuspended in hypotonic buffer A (100 mM HEPES, pH 7.9; 10 mM KCl; 0.1 M EDTA; 0.5 mM dithiothreitol; 1% nonidet P-40; and 0.5 mM phenylmethylsulfonyl fluoride) for 10 min on ice and then vortexed for 10 s. Nuclei were pelleted by centrifugation at 12,000 × g for 30 s and then resuspended in buffer C (20 mM HEPES, pH 7.9; 20% glycerol; 0.42 M NaCl; 1 mM EDTA; and 0.5 mM PMSF) for 30 min on ice. Supernatants containing nuclear proteins were collected by centrifugation at 10,000 × g for 2 min.
Western blot analysis
Total cell lysates or nuclear extract were separated on 10% SDSpolyacrylamide gels. Separated proteins were electrophoretically transferred onto nitrocellulose membranes. The membranes were probed with specific antibodies to phospho-STAT6/SAT6, PPAR-, LXR-, ABCA1, -actin, -tubulin, and histone H1 and visualized by chemiluminescence.
Real-time quantitative PCR
Gene expression was analyzed using real-time quantitative PCR (qPCR) on a StepOnePlus system (Applied Biosystems, Life Technologies, Carlsbad, CA). For each qPCR assay, 50 ng cDNA was used. The primers used were as follows:
and HPRT:
All mRNA levels were normalized to HPRT mRNA levels 28 and are reported as the fold change in expression over the control group.
Measurement of PPAR-activity
PPAR-activity was determined in nuclear extracts (8 g) from macrophages prepared using the TransAM assay kits (Active Motif, Carlsbad, CA), according to the manufacturer's instructions.
Immunocytochemistry
Cells were grown on coverslips and cultured for the indicated times equipped with a filter set at excitation wavelengths of 488 and 543 nm.
Statistical analysis
Data are expressed as the mean ± SEM. An analysis of variance was applied for multiple comparisons, and the Tukey's post-hoc test was applied where appropriate. The Student's t-test was used for comparisons of two sample means. A P-value less than 0.05 was considered statistically significant.
RESULTS
Apoptotic cells trigger STAT6 phosphorylation and PPAR-activation in mouse BMDMs and RAW 264.7 cells
Initial studies were performed to investigate the role of ABCA1 in STAT6 phosphorylation and PPAR-activation in macrophages. We first examined whether the in vitro exposure of macrophages to apoptotic Jurkat cells would result in the induction of STAT6 phosphorylation and PPAR-activation. STAT6 phosphorylation rapidly increased, peaked after 30 min, and then gradually declined, but was still higher than resting levels at 120 min in mouse BMDMs (Fig. 1A, right panel) and RAW 264.7 cells (Fig. 1B, right panel) . However, exposure to viable cells had no effect on STAT6 phosphorylation ( Fig. 1A and B, left panels). Anti-phospho-STAT6 staining was enhanced and shown to be partially localized in the nuclei of these cells, indicating the presence of an active STAT6 signal in BMDMs exposed to apoptotic
Jurkat cells ( Fig. 1C and D) . In contrast, anti-phospho-STAT6 staining was weak in BMDMs exposed to viable cells.
PPAR-mRNA and protein expression were substantially enhanced in RAW 264.7 cells, peaking at 2 and 24 h, respectively, after exposure to apoptotic cells ( Fig. 2A and B) . However, exposure to viable cells had no effect on PPAR-mRNA levels in RAW 264.7 cells at 24 h (Fig. 2C ).
PPAR-activity was enhanced up to 24 h after exposure of BMDMs and RAW 264.7 cells to apoptotic cells (Fig. 2D) . Using confocal microscopy, enhanced PPAR-expression was detected within the nuclei of BMDMs after exposure to apoptotic Jurkat cells, but not to viable cells (Fig. 2E and F) . A significant increase in PPAR-expression was confirmed in nuclear extracts of RAW 264.7 cells exposed to apoptotic cells, but not to viable cells, by western blot analysis (Fig. 2G ).
Apoptotic cells enhances LXR-and ABCA1 expression in mouse BMDMs and RAW 264.7 cells
Previous work demonstrated that the LXR-gene is a direct target of PPAR-and that these nuclear receptors cooperate in regulating macrophage ABCA1 expression. 24 Our data show that LXR-mRNA and protein expression in BMDMs and/or RAW 264.7 cells (Fig. 3A and B, respectively) were enhanced up to 24 h after exposure to apoptotic cells. Concomitant with these increases in LXR-, its target molecule ABCA1 was substantially increased at the mRNA and protein levels in BMDMs and/or RAW 264.7 cells (Fig. 3C and D, respectively) in response to apoptotic cells, peaking at 24 h.
ABCA1 mediates apoptotic cell-induced STAT6 phosphorylation, PPAR-, and LXR-expression in mouse BMDMs and RAW 264.7 cells
To determine whether ABCA1 is required for apoptotic cell-induced STAT6 phosphorylation and PPAR-activation in macrophages, experiments were performed using ABCA1-specific siRNAs. Mouse BMDMs and RAW 264.7 cells were transfected with ABCA1-specific siRNAs or negative control siRNAs, and cultured for 48 h. ABCA1
protein levels decreased by approximately 60 and 65% in BMDMs Fig. 2A and B, respectively). These data suggest that ABCA1 is required for apoptotic cell-induced STAT6 phosphorylation, PPAR-, and LXR-expression. Information Fig. 2D-G) . In addition, pretreatment with the STAT6 specific inhibitor AS1517499 inhibited the increases in mRNA and protein expression of these nuclear receptors and ABCA1 in BMDMs (Fig. 5F-I ) and RAW 264.7 cells (Supplemental Information Fig. 2H-K) .
PPAR-is required for the increases in LXRand ABCA1 expression in mouse BMDMs and RAW 264.7 cells after exposure to apoptotic cells
To confirm PPAR-engagement in mediating the increases in LXRand ABCA1, experiments were performed using PPAR--specific siRNAs. PPAR-protein levels were specifically decreased by approximately 80% in BMDMs and RAW 264.7 cells transfected with PPARsiRNAs ( Fig. 6A and Supplemental Information Fig. 3A, respectively) . and Rac1, in primary peritoneal macrophages. In contrast to the findings from their study, which showed that levels of ABCA1 mRNA peaked 2 h after in vitro exposure to apoptotic cells, our data demonstrate that ABCA1 mRNA was not increased until 12 h after apoptotic cell exposure and peaked at 24 h in BMDMs. We hypothesize that differences in experimental conditions between our study and theirs 44 led to these disparate results. Consistent with our in vitro findings, we found that that 
